Compare Magna International Inc. Common Stock (MGA) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Magna International Inc. Common Stock vs Travere Therapeutics Inc. Common Stock — how do they compare? Magna International Inc. Common Stock trades at $64.38 (market cap $17.39B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Magna International Inc. Common Stock is far larger — about 3.6× Travere Therapeutics Inc. Common Stock's market cap, and Magna International Inc. Common Stock pays a 3.03% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Magna International Inc. Common Stock for 6 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| MGA | TVTX | |
|---|---|---|
Market Cap | $17.39B | $4.88B |
Volume | 1,279,527 | 1,668,577 |
Sector | Consumer Cyclical | Health |
52-Week High | $73.05 | $67.52 |
52-Week Low | $44.65 | $26.79 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $22.42B | $5.01B |
Dividend Yield | 3.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Magna International (MGA) trades at $65.31, up 2.75% with a bullish technical signal. The stock shows strong earnings momentum with three consecutive quarterly beats and trades at attractive valuations with P/E of 24.01 and P/S of 0.43. Recent news highlights margin expansion and international growth opportunities, while cash flow remains positive despite increased capital returns.
MGA presents a favorable risk-reward profile with analyst consensus target of $69.20 (5.9% upside) and 43% buy ratings. Key catalysts include Q3 2026 earnings on October 30 and continued margin improvement, though risks include flat auto production and potential tariff impacts on North American operations.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Magna International Inc. Common Stock
Magna International Inc. is a Canada-based automotive supplier that designs, engineers, and manufactures vehicle systems and components, including body and chassis structures, seating, powertrain, and electronics, and provides complete-vehicle engineering and contract assembly, with manufacturing operations in 28 countries.
Read more on MGA →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
